Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12122839 IFNGR binding synthetic cytokines and methods of use

Patent 12122839 was granted and assigned to Synthekine on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Synthekine

Current Assignee

Synthekine

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

121228390

Patent Inventor Names

Deepti Rokkam0

Robert Kastelein0

Patrick J. Lupardus0

Date of Patent

October 22, 2024

Patent Application Number

180064840

Date Filed

August 5, 2021

Patent Citations

‌

US Patent 10421807 Interleukin-31 monoclonal antibody

‌

US Patent 8258268 Dual variable domain immunoglobulin and uses thereof

‌

US Patent 8921528 Bispecific fusion antibodies with enhanced serum half-life

‌

US Patent 8975382 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

‌

US Patent 9334331 Bispecific antibodies

‌

US Patent 10927186 T cell recruiting polypeptides based on TCR alpha/beta reactivity

Patent Primary Examiner

‌

Nora M Rooney

Patent abstract

Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 V

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12122839 IFNGR binding synthetic cytokines and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API